PCSK9 as predictor for recurrent cardiovascular disease in familial hypercholesterolemia

被引：2
作者：
Reeskamp, Laurens F. [1 ]
Tromp, Tycho R. [1 ]
Hovingh, G. Kees [1 ]
机构：
[1] Univ Amsterdam, Amsterdam UMC, Dept Vasc Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
来源：
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY | 2021年 / 28卷 / 03期
关键词：
CALCIFICATION; STATINS; EVENTS; RISK;
D O I：
10.1177/2047487319886140
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：270 / 271
页数：2
相关论文
共 50 条
  • [21] The Pharmacologic Role and Clinical Utility of PCSK9 Inhibitors for the Treatment of Hypercholesterolemia
    White, C. Michael
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2018, 23 (04) : 301 - 308
  • [22] PCSK9 Function and Cardiovascular Death The Knot Tightens
    Schwartz, Gregory G.
    Taylor, Matthew R. G.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (24) : 3115 - 3117
  • [23] Beyond Statins and PCSK9 Inhibitors: Updates in Management of Familial and Refractory Hypercholesterolemias
    Rached, Fabiana
    Santos, Raul D.
    CURRENT CARDIOLOGY REPORTS, 2021, 23 (07)
  • [24] MK-0616: an oral PCSK9 inhibitor for hypercholesterolemia treatment
    Burnett, John R.
    Hooper, Amanda J.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2023, 32 (10) : 873 - 878
  • [25] Global trends and research hotspots of PCSK9 and cardiovascular disease: a bibliometric and visual analysis
    Tang, Masong
    Yang, Sen
    Zou, Junying
    Li, Meng
    Sun, Yan
    Wang, Mengqi
    Li, Wanhan
    He, Junhui
    Chen, Ying
    Tang, Zhanyou
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2024, 11
  • [26] PCSK9 gene variations in the clinical setting of premature cardiovascular disease: A critical appraisal
    Lorca, Rebeca
    Aparicio, Andrea
    Gutierrez, Luis
    Alvarez-Velasco, Rut
    Gonzalez-Urbistondo, Francisco
    Pascual, Isaac
    Gomez, Juan
    Vazquez-Coto, Daniel
    Garcia-Lago, Claudia
    Avanzas, Pablo
    Coto, Eliecer
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2024, 413
  • [27] Effects of PCSK9 inhibitors on cancer, diabetes, and cardiovascular diseases
    Nejabat, Mojgan
    Hadizadeh, Farzin
    Almahmeed, Wael
    Sahebkar, Amirhossein
    DRUG DISCOVERY TODAY, 2025, 30 (03)
  • [28] PCSK9 Inhibitors as Adjunctive Therapies in Hypercholesterolemia: Benefits, Limitations, and Possible Alternatives
    Hamad, Mawieh
    Muhammad, Jibran Sualeh
    Rah, Bilal
    Hasan, Haydar
    Taneera, Jalal
    Soofi, Abdulsalam
    Awadallah, Samir
    ADVANCED THERAPEUTICS, 2023, 6 (09)
  • [29] PCSK9 Inhibition to Reduce Cardiovascular Risk Tempering Expectations
    Waters, David D.
    Hsue, Priscilla Y.
    CIRCULATION RESEARCH, 2017, 120 (10) : 1537 - 1539
  • [30] Exploration of PCSK9 as a Cardiovascular Risk Factor Is There a Link to the Platelet?
    Gurbel, Paul A.
    Navarese, Eliano P.
    Tantry, Udaya S.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 70 (12) : 1463 - 1466
12345